EU Inspection Complaints due to inadequate Handling of OOS Results
Recommendation

17/18 November 2026
Heidelberg, Germany
Enhanced Approach using AQbD Principles
On August 08, 2017, a Statement of Non-Compliance with GMP was published on the Eudra GMDP website for Dr. Reddy's Laboratories Ltd. in India.
The findings from several GMP inspections of the manufacturer showed that the company does not operate in compliance with European GMP requirements. The following deficiencies were viewed as critical:
In hundreds of cases, OOS results were systematically invalidated without traceable or scientifically based root-cause-analysis; the only reason given was "staff-errors".
Deviation and OOS management including protocols-, review- and reporting-systems were designed and executed in such a way that all deviations, incidents and unusual events were systematically not documented.
Furthermore, the cleaning of rooms and direct-product-contact equipment had verifiably not been performed.
The consequences include:
- Recall of already released batches
- No deliveries to the EU until a successful re-inspection has been performed
- Withdrawal of the currently valid GMP certificate
Please also see the complete Eudra GMDP "Statement of Non-Compliance with GMP" for Dr. Reddy's Laboratories Ltd. in India.
Related GMP News
02.11.2026FDA Warning Letter: When Test Procedures Allow Retesting Until an Acceptable Result is Obtained
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus


